Author: Mark Newman

Share

Smarter Diagnosis: AI Enhances Clinical Assessment of Hypercortisolism

Doctor AI will see you now — eventually. A new study from The Journal of Clinical Endocrinology & Metabolism has demonstrated how artificial intelligence (AI) can enhance the accuracy of diagnosing Cushing’s syndrome (CS), a rare but serious endocrine disorder caused by excessive cortisol production. Cushing’s syndrome is characterized by a broad spectrum of symptoms,...
Share

April 2025 Advocacy in Action

Endocrine Society Advocates to Protect Funding for NIH and Reauthorize SDP on Capitol Hill   On Wednesday, March 12, the Endocrine Society hosted a Researcher Hill Day and brought members from across the country to Washington, D.C., to meet with their senators and representatives and discuss the importance of completing the appropriations process for Fiscal Year...
Share

Endocrine Society Disappointed in Failure to Extend Medicare and Medicaid Coverage to Anti-obesity Meds

The Endocrine Society is extremely disappointed the administration has chosen not to finalize a rule that would have made anti-obesity medications more accessible to millions of Americans with obesity.  The administration decided not to implement a proposal that would have allowed Medicare and Medicaid to cover anti-obesity medications for weight loss. Many Medicare and Medicaid...
Share

Science, Advocacy, and Publishing

John_Newell-Price March 2025 has seen “Stand up for Science” events take place in cities in both the U.S. and France. Reliable, reputable research is essential for fostering advances in human health. The Endocrine Society is extremely active in advocating for science funding and health policy, with particular emphasis on the endocrine space. The Society also has...
Share

Pharma Fridays – March 28, 2025

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * CABOMETYX® Receives FDA Approval to Treat Neuroendocrine Tumors On March 26, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with...
Share

Shlomo Melmed, MB, ChB, Elected AAAS Fellow

Dr.-Shlomo-Melmed-MB-ChB-FRCP-FACP-002 Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai, has been elected Fellow of the American Association for the Advancement of Science (AAAS) — one of the world’s largest and most prestigious scientific societies and publisher of the Science journals. The lifetime honor recognizes...